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Methods 68
Selection of patients 69
For this study (EudraCT number is 2012-001244-22), 14 obese patients with a planned RYGB surgery at the University 70 Hospitals Leuven, Belgium, were recruited. Patients who had previously undergone bariatric surgery or who had renal and 71 hepatic impairment were not included in the study. Pregnant and breastfeeding women were also not included. RYGB 72 surgery was performed in all recruited patients by the same surgeon. In brief, the jejunum was divided 30 cm from the 73 ligament of Treitz and anastomosed to a 30 mL proximal gastric pouch. The jejunum was reanastomosed 120 cm distally to 74 the gastrojejunostomy. All mesenteric defects were closed. The study was approved by the Medical Ethics Committee of the 75 University Hospitals Leuven (ML8433) and all patients gave written informed consent. 76
Study design and procedure 77
A single-dose pharmacokinetic study of metoprolol tartrate (referred to as metoprolol) 200 mg immediate release 78 (Lopresor®) and controlled release (Slow-Lopresor®) was performed before and six to eight months after RYGB (on average 79 6.6 months [SD 0.63]; further referred to as six months after RYGB). Both formulations were tested in all patients before and 80 after RYGB, with an interval of at least 5 days between administration of the two formulations. The relative extent of oral 81 exposure of metoprolol from both formulations was estimated by the determination of the area under the curve (AUC 0-24h ), 82 the peak plasma concentration of metoprolol after oral administration (C max ) and the time to reach peak concentration (T max ). 83
The AUC 0-24h reflects drug absorption and drug elimination; in this paper we have mainly focused on drug absorption as a 84 RYGB mainly influences the absorption through the formation of a gastric pouch and bypass of the proximal part of the small 85 intestine. 86
Following an overnight fast of at least 10 hours, subjects came to the clinical pharmacology unit of the University Hospitals 87
Leuven. Weight and height of the subjects were measured with calibrated equipment. The weight was measured to the nearest 88 0.1 kg, with the subjects having an emptied bladder and wearing indoor clothing with empty pockets and without shoes. BMI 89 (kg/m²) was calculated by dividing the weight (kg) by the square of the height (m²). A Dual Energy X-ray Absorptiometry 90 (DXA) was performed to measure the amount of body fat mass [14] . 91
After the insertion of an intravenous catheter, the subjects ingested 200 mg of metoprolol (2 tablets of Lopresor® 100 mg or 92 1 tablet of Slow-Lopresor® 200 mg) with 150 mL of water. The tablets were taken without being broken or crushed. After 93 oral administration, blood samples were collected into heparinised tubes at 15; 30; 60; 90 minutes and 2; 2.5; 3; 3.5; 4; 5; 6; 94 7; 8; 9; 10 and 24 hours. The blood samples were centrifuged immediately after collection (1800 g, 10 min, 4°C) and plasma8 samples were stored at -20°C until analysis. At each time-point, the systolic blood pressure (SBP), diastolic blood pressure 96 (DBP) and heart rate were determined with Omron, Model M6, Digital automatic blood pressure monitor, Intellisens TM .
97
A standardised meal and a standardised snack were administered 4 hours and 8 hours after drug administration, respectively. 98
Participants had to consume the entire meal. The use of water was allowed ad libitum, except for one hour before and four 99 hours after drug administration. During the first 4 hours after administration of metoprolol, the patients had to remain semi-100 supine in bed. After the 10h-blood sample, the subjects were discharged and they had to return the next morning for the 24-h 101 blood sampling. As proton pump inhibitors, H 2 -receptor antagonists and antacids could influence the absorption of drugs, the 102 recruited patients were asked to stop these drugs during the week preceding the study. Other prescription drugs were checked 103 to verify that there were no pharmacokinetic interactions with the study drug. The morning of the study, the patients were not 104 allowed to take their medication. for metoprolol and the internal standard, respectively. 121
Calibration curves were made based on a stock solution of metoprolol in dimethyl sulfoxide and linearity was observed 122 between 1337 ng/mL and 5 ng/mL. The intra-day accuracy and precision errors were 3.3% and 6.4%, respectively, for a9 concentration of 535 ng/mL (corresponding to 2000 nM) and 3.0% and 8.6%, respectively, for a concentration of 53 ng/mL 124 (corresponding to 200 nM). The inter-day accuracy and precision errors were 6.1% and 1.0%, respectively, for a 125 concentration of 535 ng/mL, and 4.8% and 3.5%, respectively, for a concentration of 53 ng/mL. 126
Data and chapter analysis 127
The AUC 0-24h of the concentration-versus-time profiles was determined using the linear trapezoidal rule. Data are presented as 128 mean (95% confidence interval, CI), unless otherwise mentioned. To evaluate the effect of RYGB on the pharmacokinetic 129 parameters of metoprolol, AUC 0-24h , C max and T max obtained before and after surgery were compared. The paired data were 130 analysed with SPSS Statistics 22, performing a paired t-test as the assumption for normal distribution of the data was 131 accepted (Shapiro-Wilk test). The AUC 0-24h of the controlled release formulation was transformed with the logarithmic 132 function to achieve normality. For the data analysis of T max , a Wilcoxon signed-rank test was performed as normality was not 133 achieved. Multiple linear regression analysis was performed to control for confounding factors betweenthe difference inoral 134 exposure of metoprolol and: gender, age, BMI, fat percentage as measured by DXA, weight loss, systolic and diastolic blood 135 pressure and heart rate were included. No significant confounding factors were identified for AUC 0-24h ; so no adjustments for 136 these factors were made. To compare the baseline pharmacodynamic parameters a paired t-test was performed, and the 137 comparison of the pharmacodynamic profiles was carried out using a linear mixed model. Statistical significance was set at 138
p<0.05. 139
Physiologically-based pharmacokinetic modelling and simulation 140 PBPK modelling and simulation was employed using the previously developed and validated RYGB PBPK absorption 141 model, based on the obesity model by Ghobadi et al. (2011) available in the Simcyp Simulator, considering obesity related 142 changes in drug disposition [15] . The RYGB PBPK absorption model was coupled to the minimal PBPK model incorporated 143 into the Simcyp Simulator version 13.1, in order to elucidate the potential mechanism behind the observed trend in oral drug 144 exposure of metoprolol immediate and controlled release formulation before to after RYGB [13, 16, 17] . Metoprolol 145 immediate and controlled release compound files were developed based on the pre-validated metoprolol compound as 146 supplied in the Simcyp compound library. Distributional parameters describing a two-compartmental distribution behaviour 147 (V ss , V sac , k in , k out ) were estimated based on intravenous data from Regardh et al. [18] using the parameter estimation toolbox, 148 obtaining the following estimates: 2.58 L/kg, 1.89 L/kg, 5.75 h -1 and 5.09 h -1 for V ss , V sac , k in and k out , respectively. 149
Clearances via cytochrome P450 isoforms 3A4 and 2D6 were estimated using the retrograde model, back-calculating 150 intrinsic clearance (CL int ) from intravenous clearance assuming a 7% contribution by CYP3A4 (Simcyp Simulator v13.1). In 151 vitro release profiles of metoprolol immediate and controlled release formulations were obtained from Oosterhuis et al. [19] 152 and Polli et al. [20] and were fitted to a Weibull function using Matlab R2012a (Mathworks, Natick, MA, USA). For the 153 immediate release metoprolol formulation the Weibull function describing the dissolution profile derived from simulated 154 gastric fluid was directly implemented into the Simcyp Simulator. Dissolution of the controlled release formulation was 155 scaled by in vitro-in vivo correlation (IVIVC) based on fast, medium and slow extended release profiles and plasma 156 concentration-time data as reported by Eddington et al. [21] . The IVIVC produced a correction factor of 0.93 using the 157 module in Simcyp Simulator v13.1. The RYGB absorption model was adapted as per Darwich et al. [16] in order to account 158 for population-specific demographics (body weight, height, age and gender) pre and post RYGB, and surgical dimensions. 159
Furthermore, oral bioavailability (F oral ) was calculated using the following equation: 160
where F A stands for fraction of drug absorbed; F G is the fraction of drug escaping gut wall metabolism and F H stands for the 162 fraction of drug entering the portal vein escaping first pass metabolism in the liver. 163
Results
165
In this study, we recruited 14 patients (10 women, 4 men) with a mean age of 44.4 years (95% CI [38.0, 50.7]). The main 166 characteristics of the participants are shown in Table 1 . 167
The observed and predicted pharmacokinetic data are summarised in Table 2 and the observed concentration-time profiles are 168 shown in Fig. 1 After administration of the metoprolol controlled release formulation, no statistically significant difference in AUC 0-24h of 184 metoprolol was observed, although a tendency towards increased oral exposure could be observed after RYGB as the AUC 0-185 24h after oral administration of the controlled release formulation was 55.9% (95% CI [5.73, 106]) higher than before RYGB 186 (paired t-test: p=0.30). The same observation was made for the predicted data. In Fig. 2 the data from the in vivo 187 pharmacokinetic study and the predicted data for metoprolol immediate and controlled release before and after RYGB are 188
shown along with the segmental fraction of dose absorbed along the small intestine. 189
[Insert Figure 2 ] 190 [Insert Table 3 ] 191
In the simulated data, a very small reduction of 3 % in oral bioavailability (F oral ) following RYGB was predicted (see Table  192 3). 193
During the pharmacokinetic study, pharmacodynamic parameters were also monitored (Fig. 3) . Before administration of the 194 metoprolol immediate release formulation, baseline systolic blood pressure (p=0.02) and heart rate (p=0.00) were 195 significantly lower after RYGB; before administration of metoprolol controlled release, baseline systolic blood pressure 196 (p=0.01) was significantly lower after RYGB. After administration of metoprolol immediate release, there was a significant 197 interaction between time-point after administration and moment of the experiment (before or after surgery) for heart rate 198 (p=0.029) and systolic blood pressure (p<0.001), but not for diastolic blood pressure. After administration of the controlled 199 release formulation, there were no significant interaction effects regarding the pharmacodynamic parameters. Metoprolol (pK A = 9.18) is known to cross the intestinal mucosa through passive diffusion [9] . As this compound has a high 208 solubility and high permeability [8, 22] , its absorption is not expected to be altered significantly after RYGB, which was 209 indeed confirmed in this study. 210
, despite the observed tendency towards a higher oral drug exposure. 211
Besides its high solubility (>700 mg metoprolol tartrate/mL in water at 37°C) and high permeability, the absorption of 212 metoprolol by the gastrointestinal tract is rapid and complete; no site dependent absorption occurs over a large part of the 213 intestine [22, 23] . However, in view of the reduced length of the gastrointestinal tract after RYGB, the absorption may be 214 decreased. Additionally, surgery associated weight loss might result in a reduced distribution volume, which therefore may 215 compensate for a possible reduction in oral absorption postoperatively. In a previous study in obese patients, the apparent 216 distribution volume for metoprolol was shown to be higher in obese patients compared to non-obese patients with a lower 217 peak concentration [24] . This can also contribute to the tendency towards an increased oral exposure post-RYGB, since the 218 BMI and fat percentage is decreased six months post-RYGB compared to baseline. 219
Furthermore, metoprolol undergoes metabolism in the liver by CYP2D6 and to a small extent by CYP3A4, resulting in the 220 formation of metabolites (O-desmethylmetoprolol and α-hydroxymetoprolol) without a significant beta-blocking effect, [25] . 221
As no significant changes were observed in the pharmacokinetic parameters of disposition and the half-life of metoprolol 222 before and after surgery, CYP2D6 metabolism is probably the same before and after RYGB as metoprolol is a validated 223 probe drug for CYP2D6 activity [26] . Also for the controlled release formulation, no significant differences in the 224 disposition of metoprolol were observed. Both formulations contained the same salt, metoprolol tartrate, and we could 225 therefore expect these two formulations to display the same solubility properties. Previous studies have shown that the extent 226 of absorption of metoprolol is comparable along the gastrointestinal tract [27, 28] . This may explain the absence of an effect 227 on AUC 0-24h for the controlled release formulation before and after RYGB as the absorption in more distal parts of the 228 intestine can compensate for the bypassed proximal segment of the small intestine. Furthermore, for a controlled release 229 formulation based on a matrix system, as is the case here, the intestinal transit time becomes an important factor in limiting 230 absorption. In only a few studies the intestinal transit time after RYGB has been investigated. Dirksen et al. have shown that 231 14 the small intestinal transit time after a meal was slower in patients more than one year post-RYGB than in control subjects, 232 while the colonic transit rate did not differ between the groups [29] . These observations do not entirely correspond with the 233 findings of Morinigo et al., who have shown that the oro-caecal transit time, which includes pouch emptying and small 234 intestinal transit, was shorter in RYGB-patients. Other studies have already shown that the gastric emptying for liquids is 235 accelerated after RYGB [30] [31] [32] . Carswell et al. also reported on the oro-caecal transit time using sulphasalazine; in this 236 study, RYGB had no impact on the oro-caecal transit time [33] . Overall, these studies indicate that the transit time before and 237 after RYGB is probably comparable, which contributes to the similar disposition of metoprolol after administration of the 238 controlled release formulation. Although, the oral exposure after administration of the controlled release formulation had also 239 the tendency to be increased; this might be explained by the characteristics of the compound, as discussed for the immediate 240 release formulation. 241
Because it is impossible to test all the drugs on the market in clinical trials in specific patient populations, PBPK modelling 242 may be considered a complimentary approach in that it may provide potential insights as to what factors are mainly 243 responsible for observed differences in drug exposure between populations. During the last few years, PBPK modelling has 244 indeed seen an expanding area of applications, including that of post bariatric surgery patients. A pharmacokinetic model was 245 created for the different types of bariatric surgery, including RYGB, by Darwich et al [13] . The observed data of metoprolol 246 immediate and controlled release were compared to matched simulations utilising the PBPK RYGB model. The trends 247 observed in the clinical studies were comparable to the predictions made using the PBPK modelling and simulation approach. 248
However, an overprediction occurred in the first part of the concentration-time profiles, especially for the slow release 249 formulation which could probably be attributed to the lack of well-established in-vitro in-vivo correlation methods. Despite 250 this minor overprediction, the observed data were well within the 95% prediction intervals. According to simulations, the 251 trend of an increased oral exposure was mainly due to weight loss as the oral bioavailability remained almost constant before 252 and after surgery. For the observed data, weight loss could contribute to the tendency of the increased exposure of metoprolol 253 post-RYGB. 254
Based on the current results one could conclude that the PBPK modelling and simulation provides a good platform for 255 reasoning around what factors will be the most significant in determining the disposition of metoprolol following RYGB. 256
As already mentioned, metoprolol is metabolized by CYP2D6, which has a genetic heterogeneity; a different CYP2D6 257 genotype and metabolizer phenotype may thus influence the pharmacokinetics of metoprolol [11, 34] . Therefore, it may be 258 advantageous to determine the genotype of the volunteers, which was not performed in this study. However, the fact that we 259 followed the same group before and after the operation (i.e. the genotype in both groups was the same) rules out the absolute 260 necessity of genotyping. 261
It also has to be kept in mind that the expression of cytochrome P450 enzymes is the highest in duodenum and jejunum and 262 decreases towards to more distal sites of the small intestine [35] ; bypassing parts of the proximal small intestine with a high 263 abundance of CYP enzymes may therefore lead to a different effect on the bioavailability of drugs metabolized by CYP 264 enzymes, depending on the genotype. Bypassing first-pass metabolism in the proximal small intestine may also contribute to 265 the tendency of an increased exposure of metoprolol after RYGB as it results in a decreased presystemic biotransformation. 266
A similar effect has been described by Skottheim et al. [36] concerning the exposure of atorvastatin following gastric bypass 267 surgery. 268
In this study, we also explored the influence of both formulations on the pharmacodynamic parameters; the blood pressure 269
and heart rate at baseline were lower after the operation. This can be explained by the improvement of cardiovascular 270 parameters after RYGB [37] . 271
Overall, the strength of this study lies in the fact that it was performed in the same patient group before and after the 272 operation, and that the same type of surgery was performed by the same surgeon. This design helps to minimize inter-273 individual differences in metoprolol exposure before and after surgery, which is important as there are several factors 274 contributing to the inter-individual variability in the pharmacokinetics of metoprolol (such as age, first-pass metabolism and 275 intestinal absorption) [9] . 276
In the future, more challenging drugs will be studied, including low solubility compounds for which solubilisation depends 277 on intraluminal bile salt concentrations or on the residence time in the acidic environment of the stomach. 278
To conclude, the oral exposure of metoprolol immediate release and controlled release formulation was not significantly 279 different before compared to after RYGB, although a tendency towards higher exposure existed following surgery, which 280 could be explained by weight loss and a reduced presystemic biotransformation in the proximal GI-tract. The PBPK 281 modelling and simulation predicted values were similar to the observed data, confirming its validity in daily clinical practice 282 Table legends   Table 1 Characteristics of the participants, shown as mean (95% CI). Table 2 Pharmacokinetic results and predicted results for the immediate (IR) and controlled release (CR) formulation of metoprolol before and after surgery. Table 3 Predicted results for the bioavailability of metoprolol. F A , fraction of drug absorbed; F G, fraction of drug escaped gut metabolism; F H , fraction escaped first pass metabolism; F oral , oral bioavailability. 
